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Summary Tamoxifen injections were given once a week for 4 weeks to 19 rats bearing N-methyl-N-
nitrosourea (NMU)-induced mammary carcinomas. NMR spectra were collected on days 2, 7, 14, 21 and 28.
Only 42% of the tumours responded to the tamoxifen in that they regressed significantly; another 21% did not
change in size and 37% grew significantly. In the ones that did subsequently regress there were significant
changes in the NTP/Pi ratio as early as 2 days after treatment, before any detectable change in volume was
recorded, and continuing up to 21 days. The significance of these findings and the possible mechanisms
underlying the changes are discussed.
Endocrine treatments are widely used in advanced breast
cancer, but only cause remission in about 30% of patients.
Some indication as to the likelihood of response is given by
the measurement of tumour hormone receptor status (e.g.
oestrogen receptor (ER) or progesterone receptor (PR)) but
about 50% of ER-positive patients fail to respond, and about
5% of ER-negative patients do respond. Furthermore, the
median duration of response is only 20 months (Powles,
1984).
There is clearly a need for a rapid and sensitive indicator
of tumour response. Unfortunately decrease in tumour size,
as a measure of responsiveness to endocrine therapy, tends to
be slow; Powles (1984) quotes times ranging from 15 weeks
in soft tissues to 41 weeks in bone to achieve a partial
response. The technique of Magnetic Resonance Spectros-
copy (MRS) offers a way to measure the response of tumours
to various therapeutic modalities (for review see Steen, 1989).
In studies performed on oestrogen-sensitive rat mammary
tumours (Rodrigues et al., 1988) we have shown that ovari-
ectomy induced a marked change in phosphate metabolite
ratios (PCr/NTP, NTP/Pi, PCr/Pi) that could be detected at
48 h, well before any measurable regression or significant
histological changes (Stubbs et al., 1990) had taken place.
This raised the possibility that MRS (which is non-invasive
and has no known harmful effects on patients) could be used
to monitor response to endocrine therapy. Tumours that
failed to respond could be treated immediately by another
modality, instead of allowing several weeks or months for
growth and dissemination to take place.
In current medical practice the most commonly used agent
in endocrine therapy of breast cancer is tamoxifen, an oestro-
gen antagonist. In the present paper we report studies on the
use of MRS to monitor the response of NMU-induced
oestrogen-sensitive rat mammary tumours to tamoxifen.
Materials and methods
Animals and tumours
Oestrogen sensitive mammary tumours were induced in
female virgin Ludwig/Wistar/Olac rats with N-methyl-N-
nitrosourea (NMU) as detailed in Stubbs et al. (1990). After
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about 12 weeks 80% of the animals developed mammary
tumours. The tumour volumes were measured using the fol-
lowing formula:
v=I/6 (dl.d2.d3)
where dl, d2 and d3 are the length, width and depth of the
tumour.
Tamoxifen
Tamoxifen (Nolvadex) was obtained from ICI PLC, Pharma-
ceuticals Division, Unit 6, Cumberland Avenue Estate,
NW10. Tablets, which are not soluble in water, were
homogenised in Mazola oil and doses of 0.01 mg kg-' were
given intramuscularly each week for 4weeks.
NMR measurements
Tumours were examined by NMR spectroscopy when their
size was more than 1.5 cm3 (range 1.66-2.64 cm3). The
animals were anaesthetised with pentobarbitone
(30 mg kg-' i.p.) and placed within the 27 cm bore of 1.89
Tesla Oxford Research System-TMR-32 200 instrument.
Spectra were obtained at 32 MHz using a I or 1.4 cm
diameter surface coil with a pulse width of 6 or 8 tLs respec-
tively, a 3 s repetition time and 480 scans. Peak areas were
calculated using the software package supplied with the in-
strument after profile correction to remove some of the broad
signal. Due to difficulties in baseline definition and overlapp-
ing peaks these integrals may not give true chemical concent-
rations and for this reason the results are expressed as ratios
of integrals which minimises some of the uncertainties. The
reproducibility of the integrations was 100 ± 0.3% (10)
(mean ± s.e.m.). PCr was not consistently present in this set
of tumours and therefore the results reported are limited to
the integral of the ,BNTP peak (which includes contributions
mainly from ATP and GTP - see Stubbs et al., 1989) relative
to the Pi integral i.e. PNTP/Pi with means ± s.e.m.
Results
A total of 39 animals were used in this study. Twenty-five
were treated with tamoxifen and 14 were used as controls; six
of the animals died during the experiments due to the sensi-
tivity of these animals to anaesthesia, and were not included
in the results. The tumours were monitored both for volume
changes (see Figure 1) and by 31P spectroscopy (see Figures 2
and 3) at 2, 7, 14, 21 and 28 days. Of the treated animals,
eight responded showing regression to less than 50% of their
original starting volume (see Figure 1), four animals showed
no further growth, whilst seven did not respond to the
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Figure 1 The effect of tamoxifen on the volumes of rat mam-
mary tumours. The volumes prior to treatment were taken to the
100% and the subsequent changes were expressed (mean ± s.e.m.)
relative to the measurements made at day 0. 0 * responders
(n = 8), 0 0 non responders (n = 7) and 0 0 (n = 14)
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Figure 2 The effect of tamoxifen on 31P NMR spectra of rat
mammary tumours. Assignments as follows: 1. Phosphomono-
esters. 2. Pi. 3. Phosphodiesters. 4. y NTP. 5. a NTP. 6. P NTP.
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Figure 3 The effect of tamoxifen on NTP/Pi ratios in rat mam-
mary tumours. The volumes prior to treatment were taken to be
100% and the subsequent changes were expressed (mean ± s.e.m.)
relative to the measurements made at day 0. * * responders,
0 0 non responders and 0 0 controls. *P <0.05 com-
pared to controls.
treatment and continued to grow, as did all the controls. The
volumes of the responders were significantly different from
the controls (P >0.01) at all time points except Day 2.
Volume measurements showed that the non-responding
tumours grew at a similar rate to the controls (see also
Figure 1).
Spectra acquired on days 0, 7 and 14, and representative of
the responding group, are shown in Figure 2. PNTP/Pi ratios
were measured from the spectra; it is apparent from examina-
tion of the spectra that the change in the ratio occurred
because Pi decreased, and not because NTP increased (see
Figure 2). The results of all the experiments (shown in Figure
3) show that these changes were significant when compared
either to the controls or to the non-responders at 2, 7, 14 and
21 days (P <0.05) although not significant at 28 days.
The tumours in the treated group that did not regress, and
remained similar in size to the starting volume (only 4),
showed a significant increase in the NTP/Pi ratios at 2 days,
but were not significant at any other time point when com-
pared to the controls (not shown in Figure 3).
Discussion
In several studies on growing and regressing animal tumours
it has been shown that the high energy phosphate content
relative to Pi decreases as the tumours increase in size
(Evanochko et al., 1984; Rofstad et al., 1988). We and others
have attributed this to reduced oxygen delivery, due to the
tumours outgrowing their blood supply (Griffiths et al.,
1987). This hypothesis is consistent with other results on the
metabolism ofexperimental tumours. For instance, Vaupel et
al. (1987) found that small human mammary carcinoma
xenografts grown in nude rats have a higher oxygen con-
sumption than that of normal post-menopausal human
breast and that both oxygen consumption and tumour blood
flow decreased as the tumours increased in size. On the otherMONITORING TUMOUR RESPONSE TO TAMOXIFEN USING MRS 903
hand, when a tumour responds to chemotherapy (Ng et al.,
1982; Steen et al., 1988), radiotherapy (Evanochko et al.,
1983; Tozer et al., 1989) or endocrine therapy (Griffiths et al.,
1987; Rodrigues et al., 1988; Stubbs et al., 1990) the opposite
effect is usually observed - the ratios of high energy phos-
phates (PCr and NTP) relative to Pi decrease, sometimes
before any detectable change in the volume is recorded (Rod-
rigues et al., 1988) and before there are any detectable histo-
logical changes (Stubbs et al., 1990).
Steen (1989) has reviewed reports of such paradoxical
improvements in the ratio of high energy phosphates to Pi in
experimental tumours after various forms of therapy, which
he terms 'metabolic activation'. He lists five hypotheses to
account for the effect: (a) killing of tumour cells and recruit-
ment of host macrophages, thus increasing the proportion of
normal cells vs cancer cells; (b) killing tumour cells, reducing
competition for nutrients and oxygen; (c) preferential killing
of 'low energy' cells or recruitment of quiescent cells into a
metabolically more active form; (d) cell killing reducing
tumoural interstitial pressure, thus improving blood flow; (e)
chemotherapy directly increasing tumour blood flow or capil-
lary permeability.
We have argued (Griffiths et al., 1987; Rodrigues et al.,
1988) that the very rapid (<2 days) increase in NTP/Pi in
tumours that repond to endocrine treatment suggests that as
the stimulus to growth (oestrogen in this case) ceases, the
demand for ATP falls and the supply of oxygen and other
nutrients is again sufficient (Griffiths et al., 1987). Alterna-
tively, or in addition to this mechanism, the tumour blood
supply might be improved either directly by tamoxifen itself
or as a consequence of reduced oestrogen concentration. We
have shown, in the case of ovariectomy, that the MRS
changes at 48 h precede any alteration in the cell population
(Stubbs et al., 1990). It is likely that this would be true for
other endocrine treatments such as 4-hydroxyandrostenedione
(Griffiths et al., 1987) and tamoxifen (this paper). If so, it
would appear that these early changes cannot be accounted
for by mechanismss (a), (b) and (d) suggested by Steen.
Mechanism (c) includes two hypotheses: preferential killing
of low energy cells (excluded) and recruitment of 'quiescent'
cells into a metabolically more active form. The latter
hypothesis seems to assume that tumours contain a popula-
tion of cells in which low NTP or PCr, or high Pi, or both
are due, not to an inadequate oxygen or nutrient supply, but
to a reversible control mechanism. No metabolic control
mechanisms of this kind have been described, to our
knowledge. Mechanism (e) assumes a direct effect (either of
tamoxifen itself, or by reduction in oestrogen concentration
in the present case) on tumour vasculature. There is no
evidence for this hypothesis in the present instance, but it
cannot be excluded. Radiotherapy appears to increase NTP/
Pi by improving tumour blood flow (Tozer et al., 1989).
The reduction in ATP demand that we have postulated
after endocrine therapy would also be expected to occur after
other treatment modalities that suppress tumour growth. It
should therefore be included in the list of factors that give
rise to the overall change in the 31P spectrum of the tumour.
In other cases one of the other factors may play a more
important role.
Since MRS is a non-invasive technique, determination of
tumour metabolic status during anticancer therapy may be
clinically useful, provided that these effects can be repro-
duced in patients. The early rise of NTP/Pi ratios in the
tumours which responded to the tamoxifen treatment and the
fall in those which did not respond, could assist the choice of
the most appropriate treatment for individual patients. In the
case of tumours that did not respond the switch in the
treatment would be more rapid than at present when one has
to wait for measurable tumour regression to suggest the
eventual response. Information of this kind would also be
useful in testing drug analogues and dose schedules.
Our hypothesis to explain the rise in NTP/Pi observed in
rat tumours soon after initiation of endocrine therapy is that
the reduction in demand for oxygen and other nutrients
following cessation of growth allows repletion of high energy
phosphate pools and a reduction in accumulated Pi. Would
human tumours be expected to show this effect? It seems
clear that the energy demand associated with tumour cell
growth would be reduced following successful endocrine
therapy. However, this might not be manifest in human
breast cancers if their energy requirements during normal
growth can be met by their blood supply.
Steen's review (1989) lists a series of therapeutic studies in
patients monitored by 31p MRS and reports that increases in
the NTP/Pi and/or PCr/Pi ratios occurred in the majority of
cases. Ng et al. (1989) reported three cases of advanced
mammary tumours treated with combined chemotherapy and
radiotherapy. In all three, the PME/ATP and phosphodiester/
ATP ratios decreased after therapy. Glaholm et al. (1989)
have reported that the major change in the 31P MRS spect-
rum of a human breast tumour after tamoxifen therapy was
a fall in the phosphomenoester peak; the aNTP peak
decreased in size, though less markedly than the PME peak.
These results are too preliminary to provide a definitive
answer to the question posed in a previous paragraph. Larger
studies will be needed to show whether the effect we see in
rat tumours commonly occur in patients.
The work reported in this paper was supported by the Cancer
Research Campaign, UK.
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